Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063008 | 0.85 | MAPK14 (0.69) | CCR3MAPK14CHRM2ACHEHTR4 | |
| SCHEMBL1063085 | 0.83 | CCR3 (0.72) | CCR3MAPK14CHRM2OXTRACHE | |
| SCHEMBL1056193 | 0.82 | CCR3 (0.69) | CCR3MAPK14CHRM2OXTRACHE | |
| SCHEMBL18840706 | 0.79 | CCR3 (1.00) | CCR3MAPK14CHRM2 | |
| SCHEMBL95512 | 0.78 | HTR2B (0.52) | CCR3MAPK14MGLLMEN1KMT2A | |
| SCHEMBL7651343 | 0.77 | MGLL (0.66) | MGLLMEN1KMT2A | |
| SCHEMBL3455294 | 0.77 | MAPK14 (0.63) | CCR3MAPK14OXTRMGLLGHSR | |
| SCHEMBL8534513 | 0.74 | MAPK14 (0.64) | CCR3MAPK14OXTRMGLLGHSR | |
| SCHEMBL30329646 | 0.74 | MAPK14 (0.64) | CCR3MAPK14CHRM2OXTRMGLL | |
| SCHEMBL22216445 | 0.74 | MAPK14 (0.64) | CCR3MAPK14CHRM2OXTRMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1987060-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| CN-101102787-A | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA INC (US) | 2008-01-09 | — | — | CN | disclosed |
| WO-2007092537-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | CCR3 811/4885MAPK14 2828/4885CHRM2 3906/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | CCR3 988/4885MAPK14 2215/4885CHRM2 4618/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | CCR3 811/4885MAPK14 2828/4885CHRM2 3906/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | CCR3 1159/4885MAPK14 2287/4885CHRM2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.